Trials / Completed
CompletedNCT00539396
A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine
A Phase 2 Randomized, Open Label, Multi-Center Study of the Use of Prandial Inhaled Technosphere Insulin in Combination With Basal Subcutaneous Lantus as Basal Insulin Versus Prandial Subcutaneous NovoRapid in Combination With Basal Subcutaneous Lantus Insulin in Subjects With Type 1 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Mannkind Corporation · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A 3 month, randomized, open label, multi-center study of Technosphere/Insulin compared to insulin aspart in subjects with type 1 diabetes mellitus receiving insulin glargine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Technosphere Insulin |
Timeline
- Start date
- 2005-03-01
- Completion
- 2005-12-01
- First posted
- 2007-10-04
- Last updated
- 2009-10-14
Source: ClinicalTrials.gov record NCT00539396. Inclusion in this directory is not an endorsement.